Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome
Compositions comprising fatty acid analogs are provided for treating metabolic syndrome, anemia, cancer, cardiovascular disease, diabetes, dyslipidemia, hypertension, inflammation, insulin resistance, prediabetes, fatty liver disease, steatohepatitis, iron overload, neurodegenerative diseases, including Alzheimer's disease and other forms of dementia, and other related conditions. Methods for the diagnosis and monitoring of metabolic syndrome and other conditions are also provided.
1. A method of treatment or prophylaxis of a condition selected from the group consisting of metabolic syndrome, cardiovascular disease, diabetes, type 2 diabetes, anemia, dyslipidemia, hypertension, inflammation, a chronic inflammatory disease, rheumatoid arthritis, insulin resistance, a fibrotic disease, prediabetes, fatty liver disease, steatohepatitis, iron overload, and nonalcoholic steatohepatitis, comprising:
administering to a patient in need thereof a pharmaceutical composition comprising an effective amount of 2-methylpentadecanoic acid, or pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein the pharmaceutical composition is in a unit dosage form.
3. The method of claim 1 , comprising from 0.01 mg to 10000 mg of the 2-methylpentadecanoic acid, or pharmaceutically acceptable salt thereof.
4. The method of claim 1 , for the treatment or prophylaxis of a fibrotic disease.
5. The method of claim 4 , wherein the fibrotic disease is selected from the group consisting of steatohepatitis and nonalcoholic steatohepatitis.
6. The method of claim 1 , wherein the condition is nonalcoholic steatohepatitis.
7. The method of claim 1 , wherein the condition is metabolic syndrome.
8. The method of claim 1 , wherein the condition is cardiovascular disease.
9. The method of claim 1 , wherein the condition is diabetes.
10. The method of claim 1 , wherein the condition is type 2 diabetes.
11. The method of claim 1 , wherein the condition is dyslipidemia.
12. The method of claim 1 , wherein the condition is hypertension.
13. The method of claim 1 , wherein the condition is inflammation.
14. The method of claim 1 , wherein the condition is a chronic inflammatory disease.
15. The method of claim 1 , wherein the condition is rheumatoid arthritis.
16. The method of claim 1 , wherein the condition is insulin resistance.
17. The method of claim 1 , wherein the condition is prediabetes.
18. The method of claim 1 , wherein the condition is fatty liver disease.
19. The method of claim 1 , wherein the condition is iron overload.